Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Recruiting Not applicable Interventional Accepts healthy volunteers

Dietary Peanuts and Nutrition-Related Outcomes

NCT07244458
Conditions
Dietary Change, Obesity & Overweight, Food Acceptance
Interventions
Peanuts, Dual-energy X-ray absorptiometry (DEXA) scans
Dietary Supplement · Procedure
Lead sponsor
Ian J. Neeland, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Clevland, Ohio
Conditions
Type 2 Diabetes (T2DM)
Interventions
SGLT-2 inhibitor, GLP1-RA
Drug
Lead sponsor
MaryAnn Banerji
Other
Eligibility
24 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Type 2 Diabetes
Interventions
AZD0186, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Glendale, California
Conditions
Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
Interventions
Semaglutide Injectable Product, Lifestyle Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
HIV, Alcohol, Smoking Cigarette, Cardiovascular Disease Prevention
Interventions
Semaglutide (Rybelsus®), Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacogenomics of GLP1 Receptor Agonists

NCT05762744
Conditions
Type 2 Diabetes
Interventions
Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Conditions
Weight Maintenance
Interventions
Digital Behavioral Application
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Not applicable Interventional

Food and Fitness With Medicine (FFWM)

NCT07027995
Conditions
Cardiovascular Kidney Metabolic Syndrome, Type 2 Diabetes
Interventions
Exercise is Medicine (EIM), Culinary Education, Food is Medicine, Nutrition Counseling, Participant Website
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Columbus, Ohio • Upper Arlington, Ohio
Conditions
Lymphedema
Interventions
GLP-1 Receptor Agonists
Drug
Lead sponsor
Advanced Reconstructive Surgery Alliance
Government
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Red Bank, New Jersey • Westwood, New Jersey
Conditions
Severe Obesity, Obesity, BMI Greater Than 30
Interventions
Tirzepatide, Standard of Care post-gastric bypass
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Diabetes Mellitus, Type 2
Interventions
GLP-1 receptor agonist, Insulin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Obesity or Overweight
Interventions
Maridebart Cafraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
43
States / cities
Pelham, Alabama • Chandler, Arizona • Sun City, Arizona + 37 more
Completed Phase 2 Interventional Results available

Daily Liraglutide for Nicotine Dependence

NCT03712098
Conditions
Smoking Cessation, Weight, Body
Interventions
Liraglutide, Placebo, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
Rebecca Ashare
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania